Stanley Capital Acquires Drug Safety and Pharmacovigilance Services Solutions

February 7, 2022

Willkie represented Stanley Capital Partners in its acquisition of Drug Safety and Pharmacovigilance Services Solutions from Clario.

On January 31, private equity firm Stanley Capital Partners announced its acquisition of Drug Safety and Pharmacovigilance Services Solutions (DSS), a leading global provider of pharmacovigilance, from Clario.

DSS is a leader in providing outsourced services to support clinical safety and pharmacovigilance commitments. DSS, headquartered in Delaware, has over 2,500 staff located in the EU, US, Japan and India, supporting over 35 long-term clients. Services to these clients span the full range of drug safety and pharmacovigilance services, which involves collecting, detecting, evaluating, assessing, and disseminating data on adverse effects associated with clinical and commercial medicinal products.

Stanley Capital Partners is a European and US-focused mid-market private equity firm using research and technology to identify opportunities in the growing sustainable investment sectors of resource efficiency, healthcare and technology.

The Willkie team was led by partners Gavin Gordon and Dvir Oren, and included partners Solomon Wifa and Rahul Saha, counsel Jonathan Konoff and associate Amelia Doughty.